OvaScience Inc (NASDAQ:OVAS)’s share price rose 2.5% during mid-day trading on Thursday . The stock traded as high as $0.82 and last traded at $0.77. Approximately 151,823 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 685,962 shares. The stock had previously closed at $0.79.
OVAS has been the subject of several research analyst reports. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Wednesday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a research report on Friday, March 16th.
The stock has a market cap of $26.40, a PE ratio of -0.61 and a beta of 3.20.
OvaScience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. OvaScience had a negative return on equity of 60.06% and a negative net margin of 17,338.78%. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.10 million. research analysts predict that OvaScience Inc will post -1.21 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP bought a new stake in shares of OvaScience during the fourth quarter worth $342,000. Deutsche Bank AG raised its position in shares of OvaScience by 7,476.4% during the fourth quarter. Deutsche Bank AG now owns 517,693 shares of the biotechnology company’s stock worth $724,000 after acquiring an additional 510,860 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of OvaScience by 6,531.3% during the fourth quarter. Renaissance Technologies LLC now owns 782,165 shares of the biotechnology company’s stock worth $1,095,000 after acquiring an additional 770,370 shares during the last quarter. Hedge funds and other institutional investors own 43.88% of the company’s stock.
WARNING: “OvaScience (OVAS) Stock Price Up -2.5%” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/05/ovascience-ovas-stock-price-up-2-5.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.